Sky Labs Valuation Multiples

Sky Labs is valued at $98M as of November 2026, a 16.5x revenue multiple. In the last fiscal year, Sky Labs revenue was $6M and Sky Labs EBITDA was ($42M).

Sky Labs Overview

About Sky Labs

Sky Labs Inc is engaged in the business of development, manufacturing, and sales of wearable medical devices and data platforms capable of continuously measuring and analyzing the vital signs of patients with chronic diseases even in non-hospital environments. Its flagship product is 'CART BP pro,' a cuffless ring-type blood pressure monitoring device. Based on a PPG sensor, it measures blood pressure and transmits data to the cloud, which is utilized by medical professionals for diagnosis and patient management. Its product solutions are a photoplethysmography (PPG) sensor, a deep learning algorithm, Automatic blood pressure measurement, and Various platforms.


Founded

2015

HQ

South Korea

Employees

N/A

Website

skylabs.io

Financials (Last FY)

Revenue: $6M
EBITDA: ($42M)

EV

$98M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sky Labs Financials

Sky Labs reported last fiscal year revenue of $6M and negative EBITDA of ($42M).

In the same fiscal year, Sky Labs generated $3M in gross profit, ($42M) in EBITDA losses, and had net loss of ($47M).


Sky Labs P&L

In the most recent fiscal year, Sky Labs reported revenue of $6M and EBITDA of ($42M).

Sky Labs is unprofitable as of last fiscal year, with gross margin of 49%, EBITDA margin of (706%), and net margin of (794%).

See analyst estimates for Sky Labs
Last FY2025202620272028
Revenue$6M$6M
Gross Profit$3M$3M
Gross Margin49%49%
EBITDA($42M)($42M)
EBITDA Margin(706%)(706%)
EBIT Margin(186%)(186%)
Net Profit($47M)($47M)
Net Margin(794%)(794%)
Net Debt($14M)-

Financial data powered by Morningstar, Inc.

Sky Labs Stock Performance

Sky Labs has current market cap of $98M, and enterprise value of $98M.

Market Cap Evolution


Sky Labs' stock price is $5.22.

Sky Labs has an EPS (earnings per share) of $-2.52.

See more trading valuation data for Sky Labs
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$98M$98M1.5%---$-2.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sky Labs Valuation Multiples

Sky Labs trades at 16.5x EV/Revenue multiple, and (2.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Sky Labs

Sky Labs Financial Valuation Multiples

As of November 19, 2026, Sky Labs has market cap of $98M and EV of $98M.

Sky Labs has a P/E ratio of (2.1x).

Last FY2025202620272028
EV/Revenue16.5x16.5x
EV/EBITDA(2.3x)(2.3x)
EV/EBIT(8.9x)(8.9x)
EV/Gross Profit33.4x33.4x
P/E(2.1x)(2.1x)
EV/FCF(9.2x)(9.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sky Labs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sky Labs Margins & Growth Rates

Sky Labs grew revenue by 29% but net profit decreased by 76% in the last fiscal year.

In the most recent fiscal year, Sky Labs reported gross margin of 49%, EBITDA margin of (706%), and net margin of (794%).

See estimated margins and future growth rates for Sky Labs

Sky Labs Margins

Last FY20252026202720282029
Gross Margin49%49%51%
EBITDA Margin(706%)(706%)-
EBIT Margin(186%)(186%)(151%)
Net Margin(794%)(794%)(149%)
FCF Margin(179%)(179%)-

Sky Labs Growth Rates

FY+1/FY25/2626/2727/2828/29
Revenue Growth29%29%
Gross Profit Growth34%34%
EBIT Growth5%5%
Net Profit Growth(76%)(76%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Sky Labs Operational KPIs

Access forward-looking KPIs for Sky Labs
Last FY2025202620272028
S&M Expenses to Revenue45%45%
G&A Expenses to Revenue11%11%
R&D Expenses to Revenue123%123%
Opex to Revenue235%235%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sky Labs Competitors

Sky Labs competitors include Viromed Medical, Cumberland, Optiscan Imaging, Quanterix, Onyx Healthcare, Sisram Medical, Vivani Medical, MEZOO, Perspective Therapeutics and Guerbet.

Most Sky Labs public comparables operate across Wearables, Medical Devices and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Viromed Medical$6M($377K)17.4x9.3x(258.6x)62.9x
Cumberland$45M$2M0.5x-8.9x-
Optiscan Imaging$302K($5M)297.2x-(18.7x)-
Quanterix$139M($102M)0.4x0.4x(0.5x)(0.8x)
Onyx Healthcare$40M$4M2.3x-20.9x-
Sisram Medical$365M$48M0.4x0.4x2.7x3.1x
Vivani Medical-($26M)--(3.7x)-
MEZOO$5M-17.3x17.3x--

This data is available for Pro users. Sign up to see all Sky Labs competitors and their valuation data.

Start Free Trial

Sky Labs VC Funding History

Before going public, Sky Labs raised $42M in total equity funding, across 4 rounds.


Sky Labs Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Sep-23Series CSJG Partners; Devsisters Ventures; Korea Development Bank; K2 Investment Partners; Open Water Investment$16M-Sky Labs is a South Korean healthcare company founded in 2015 that develops AI-based ring-type medical devices for heart monitoring, specifically designed to detect atrial fibrillation. The company's proprietary algorithm achieves 98% accuracy in AF detection. In September 2023, Sky Labs completed a Series C funding round of $15.49 million led by investors including Korea Development Bank, Devsisters Ventures, K2 Investment Partners, Openwater Investment, and SJ Investment Partners. This round marked a significant milestone in the company's growth trajectory. As of December 2025, Sky Labs had raised a total of $88.7 million across multiple funding rounds, indicating strong investor confidence in its preventative healthcare platform targeting the global wearable medical device market.
Jun-21Series BKB Investment; Korea Investment Partners; MORU Asset Management; LB Investment; Soo Investment Capital; Atinum Investment$20M-Sky Labs is a South Korea-based preventative healthcare company founded in 2015, developing AI-based ring-type wearable medical devices like CART-I for continuous atrial fibrillation detection with 98% accuracy using vital signal big data. The company finalized a Series B funding round attracting USD 20 million, matching the investors (Atinum Partners, KB Investment as lead, Korea Investment Partners, LB Investment, MORU Asset Management, Soo Investment Capital) and approximate date of June 2021, with plans to expand into global markets and develop more health monitoring wearables. Total funding across rounds reached approximately $34.3M to $48.47M by later dates, with subsequent Series C rounds like $15.49M in 2023 from other investors including Devsisters Ventures and Korea Development Bank.
Nov-20SeedChong Kun Dang Pharmaceutical Corp.$2M--
Oct-19Series AMORU Asset Management; TBT Partners; Soo Investment Capital$4M-Sky Labs raised funding across multiple rounds, including a Seed VC round on October 16, 2019. The investors for this specific round match MORU Asset Management, Soo Investment Capital, and lead investor TBT, though amount and valuation details are not disclosed. The company has completed 8 funding rounds overall, with TBT listed among 17 total investors. Sky Labs' latest round was a Series C for $15.49M on September 22, 2023, led by investors including Devsisters Ventures, K2 Investment Partners, Korea Development Bank, Openwater Investment, and SJ Investment Partners. Total funding raised by Sky Labs amounts to $38.21M.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sky Labs

When was Sky Labs founded?Sky Labs was founded in 2015.
Where is Sky Labs headquartered?Sky Labs is headquartered in South Korea.
Is Sky Labs publicly listed?Yes, Sky Labs is a public company listed on Korea Exchange.
What is the stock symbol of Sky Labs?Sky Labs trades under 386380 ticker.
When did Sky Labs go public?Sky Labs went public in 2026.
Who are competitors of Sky Labs?Sky Labs main competitors include Viromed Medical, Cumberland, Optiscan Imaging, Quanterix, Onyx Healthcare, Sisram Medical, Vivani Medical, MEZOO, Perspective Therapeutics, Guerbet.
What is the current market cap of Sky Labs?Sky Labs' current market cap is $98M.
What is the current revenue of Sky Labs?Sky Labs' last fiscal year revenue is $6M.
What is the current revenue growth of Sky Labs?Sky Labs revenue growth (vs. last FY) is 29%.
What is the current EV/Revenue multiple of Sky Labs?Current revenue multiple of Sky Labs is 16.5x.
Is Sky Labs profitable?No, Sky Labs is not profitable.
How many companies Sky Labs has acquired to date?Sky Labs hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sky Labs has invested to date?Sky Labs hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sky Labs

Lists including Sky Labs

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial